Medical Patent Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Myopathy
Merck and Schering-Plough to Develop Another New Cholesterol Lowering Medicine
April 11th, 2007
Merck & Co., Inc. (NYSE: MRK) announced an agreement to commence development of an ezetimibe and atorvastatin combination product in collaboration with Schering-Plough Corporation. Merck and Schering-Plough are the two parent companies of Merck/Schering-Plough Pharmaceuticals, a joint venture that was formed in 2000 to develop and market in the United States new prescription medicines in cholesterol management and respiratory disease. The cholesterol collaboration was expanded in 2001 and includes worldwide markets (excluding Japan). The joint venture/partnership also markets ZETIA(R) (ezetimibe) and VYTORIN(R) (ezetimibe/simvastatin) in the U.S. and these medicines are...
Source: Medical Patent Law Weekly (2007-04-11)
|
